The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 13 April 2026•Updated 15 April 2026•

1 min read

Biohaven Stock Downgraded Following FDA Regulatory Setback for Troriluzole

Key Facts

1Biohaven stock saw a significant rally on Monday following a positive recommendation from a market pundit.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: Headline and body updated to reflect the rating downgrade from 'Strong Buy' to 'Hold' following the FDA's rejection of troriluzole and the company's strategic pivot to its obesity pipeline.

Biohaven Ltd. (BHVN) has been downgraded from 'Strong Buy' to 'Hold' following a Complete Response Letter (CRL) from the FDA regarding its drug troriluzole for Spinocerebellar Ataxia. This regulatory setback has prompted the company to pivot its strategic focus toward other late-stage pipeline programs, including taldefgrobep alfa for obesity treatment. Investors are now looking toward the second half of 2026 for phase 2 proof-of-concept data on the obesity candidate. Additionally, the company is prioritizing its Kv7 activator, Opakalim, and its protein degrader platforms, BHV-1400 and BHV-1300. While previous analyst sentiment was highly bullish, the current shift reflects a more cautious outlook as the company navigates regulatory hurdles and extended data timelines.